No registrations found.
ID
Source
Brief title
Health condition
gut microbiota, obesity, fat adipose tissue
Sponsors and support
Intervention
Outcome measures
Primary outcome
Expression of genes in adipose tissue will be compared to gut microbiota composition.
Secondary outcome
We will try to relate regulation of genes to plasma markers of inflammation.
Background summary
Objective: To investigate correlations between gene expression in adipocytes and gut microbiota composition in relation to plasma markers of inflammation.
Study design: Cross-sectional design.
Study Population: Healthy men and women scheduled for elective laparoscopic cholecystectomy.
Outcome measures: Expression of human genes will be first tested on Affimetrix microarrays and genes of interest will thereafter be assessed by quantitative real-time RT-PCR. These genes in adipose tissue will be compared to gut microbiota composition. Finally we will try to relate regulation of genes to plasma markers of inflammation.
Sample Size: It is estimated that a total of 200 patients (100 males and 100 females) are needed.
Study objective
We hypothesize that genetically programmed developmental differences in adipocytes are under direct regulation of fecal flora composition which thus plays an important role in obesity, body fat distribution ans systhemic inflammation.
Study design
Cross-sectional design, only 1 timepoint.
Intervention
During the planned surgery visceral and subcutaneous biopsies will be obtained. In all patients venous blood samples will be taken and the patients will collect a feces sample.
A. Vrieze
Academic Medical Center, room F4-256
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5665983
a.vrieze@amc.uva.nl
A. Vrieze
Academic Medical Center, room F4-256
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5665983
a.vrieze@amc.uva.nl
Inclusion criteria
1. Healthy men and women, scheduled for elective laparoscopic cholecystectomy;
2. Age 18-85 yrs;
3. BMI 18-45 kg/m2.
Exclusion criteria
1. Generalized inflammation;
2. Antibiotic use last three months;
3. Malignant disease;
4. Metformin use.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL2211 |
| NTR-old | NTR2335 |
| Other | CCMO : 29210 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |